All Blogs

Aug 16, 2022

Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...

Aug 15, 2022

Congenital adrenal hyperplasia (CAH) is a rare inherited autosomal recessive disorder defined by a lack of one of the enzymes required to produce specific hormones. In the United States and Europe, the most prevalent type of CAH, 21 hydroxylase deficiency, affects around 1:10,000 to 1:15,000 people. The estimated C...

Aug 12, 2022

Molluscum contagiosum, often known as water warts, is a common superficial skin disease caused by the poxvirus. The molluscum contagiosum virus (MCV) is one of the world's 50 most common diseases. It mostly affects school-aged children, sexually active young adults, and immunocompromised people.  As per our...

Aug 11, 2022

Rapid Medical Obtains FDA Clearance for the World's Smallest and Only Adjustable Thrombectomy Device  On July 26, 2022, Rapid Medical, a leading developer of advanced neurovascular devices, received Food and Drug Administration (FDA) 510(k) clearance for TIGERTRIEVER™13 for large vessel occlusions.&n...

Aug 10, 2022

Over the past two years, the coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the global healthcare industry. The pandemic has resulted in a substantial spike in demand for at-home services. Similarly, three has been a great jump in the telemedicine industry. In particular, the need for Telep...

Aug 09, 2022

FDA Approves AstraZeneca’s Enhertu as First Targeted Therapy for HER2-low Cancer Enhertu, developed by AstraZeneca and Daiichi Sankyo, has been approved by the FDA as the first targeted therapy for HER2-low breast cancer, a new subtype of the disease previously categorized as HER2-negative. It has the potential ...

Aug 08, 2022

Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history and low healing rates. Despite current management therapies, the disease has the potential to become severe and devastating for many patients over time. Dystrophic epidermolysis bullosa is classified into six types: dominant dyst...

Aug 05, 2022

Progressive multifocal leukoencephalopathy is a severe, progressive, and lethal demyelinating disease that presents in immunocompromised states. It is a rare indication, with just over 1.5K PML diagnosed incident cases in the United States, per DelveInsight analysis. It occurs in the setting of predisposing immunos...

Aug 04, 2022

iRhythm receives FDA clearance for ZEUS System for Zio watch iRhythm Technologies, a leading digital healthcare solutions firm focused on advancing cardiac care, announced that it received FDA 510(k) clearance for the ZEUS (Zio ECG Utilization Software) System for the Zio Watch. It is produced in partnership wit...

Aug 03, 2022

Artificial Intelligence for Mental Health and Mental Illnesses: An Overview As per the latest findings, the prevalence of Mental Health has grown significantly over the past two-three decades. The growth has been registered in almost every country worldwide. People of any age, race, religion or economic status c...